Clinical Therapeutics/New Technology-Pharmacological Treatment of Complications

Clinical Therapeutics/New Technology-Pharmacological Treatment of Complications

You have access
Worsening of Glycemic Control in a Patient With Fulminant Type 1 Diabetes Receiving Sensor-Augmented Pump Therapy: A Case of Extensive Localized Lipoatrophy Requiring Attention in Relation to Cannula Insertion Sites
Keiko Koide, Koichiro Azuma, Yoshihito Atsumi

Clinical Diabetes Oct 2021, cd210035; DOI: 10.2337/cd21-0035
Open Access
Renoprotective Effects of the Combination of Empagliflozin and Liraglutide Compared With Roux-en-Y Gastric Bypass in Early-Stage Diabetic Kidney Disease: A Post Hoc Analysis of the Microvascular Outcomes after Metabolic Surgery (MOMS) Randomized Controlled Clinical Trial
Ricardo V. Cohen, Tarissa Beatrice Zanata Petry, Alexander Dimitri Miras, Cristina Mamédio Aboud, Brett Johnson, Tiago Mendonça dos Santos, Carel W. le Roux

Diabetes Care Oct 2021, 44 (10) e177-e179; DOI: 10.2337/dc21-1192
Open Access
Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
Ele Ferrannini, Julio Rosenstock

Diabetes Care Mar 2021, 44 (3) 641-646; DOI: 10.2337/dc20-0913
You have access
Dasiglucagon: A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia Results of Phase 3 Randomized Double-Blind Clinical Trial
Thomas R. Pieber, Ronnie Aronson, Ulrike Hövelmann, Julie Willard, Leona Plum-Mörschel, Kim M. Knudsen, Benedikte Bandak, Ramin Tehranchi

Diabetes Care Apr 2021, dc202995; DOI: 10.2337/DC20-2995
You have access
Glucagon-Like Peptide 1 Receptor Agonists and Chronic Lower Respiratory Disease Exacerbations Among Patients With Type 2 Diabetes
Yasser Albogami, Kenneth Cusi, Michael J. Daniels, Yu-Jung J. Wei, Almut G. Winterstein

Diabetes Care Jun 2021, 44 (6) 1344-1352; DOI: 10.2337/dc20-1794
Open Access
Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis
David C. Klonoff, Jordan C. Messler, Guillermo E. Umpierrez, Limin Peng, Robby Booth, Jennifer Crowe, Valerie Garrett, Raymie McFarland, Francisco J. Pasquel

Diabetes Care Feb 2021, 44 (2) 578-585; DOI: 10.2337/dc20-1857
You have access
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion
Carolina Solis-Herrera, Giuseppe Daniele, Mariam Alatrach, Christina Agyin, Curtis Triplitt, John Adams, Rupal Patel, Amalia Gastaldelli, Henri Honka, Xi Chen, Muhammad Abdul-Ghani, Eugenio Cersosimo, Stephano Del Prato, Ralph DeFronzo

Diabetes Care May 2020, 43 (5) 1065-1069; DOI: 10.2337/dc19-2177
You have access
Pharmacist-Provided Diabetes Education and Management in a Diverse, Medically Underserved Population
Kristina Wood Naseman, Andrew S. Faiella, Garrett M. Lambert

Diabetes Spectrum May 2020, 33 (2) 210-214; DOI: 10.2337/ds19-0048
Open Access
Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming
Angelo Avogaro, Gian Paolo Fadini, Stefano Del Prato

Diabetes Care Mar 2020, 43 (3) 501-507; DOI: 10.2337/dc19-1410
Open Access
Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Lindsay E. Clegg, Hiddo J.L. Heerspink, Robert C. Penland, Weifeng Tang, David W. Boulton, Srinivas Bachina, Robert D. Fox, Peter Fenici, Marcus Thuresson, Robert J. Mentz, Adrian F. Hernandez, Rury R. Holman

Diabetes Care Feb 2019, 42 (2) 318-326; DOI: 10.2337/dc18-1871

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Pharmacological Treatment of Complications

Pages

Navigate

More Information

Other ADA Resources